Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19
Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. Journal Of Substance Use And Addiction Treatment 2020, 122: 108214. PMID: 33248862, PMCID: PMC7685132, DOI: 10.1016/j.jsat.2020.108214.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersTreatment optionsBuprenorphine accessPatient's homeCOVID-19Stark racial disparitiesRacial disparitiesConsiderable riskTelemedicine uptakeCommunity pharmaciesBuprenorphineMethadoneMedicationsSocioeconomic disparitiesPatientsDisordersRiskPre COVID-19DisparitiesHomeOptionsUptakeGeographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]
Nguemeni Tiako M, Culhane J, Meisel Z. Geographic Distribution of Medicaid-Claimant OB-GYNs Approved to Prescribe Buprenorphine for Opioid Use Disorder [15E]. Obstetrics And Gynecology 2020, 135: 53s-53s. DOI: 10.1097/01.aog.0000663556.94003.be.Peer-Reviewed Original ResearchOpioid use disorderNeonatal abstinence syndromeOb-gynsUse disordersIncidence of NASHighest opioid overdose death ratesGuideline-recommended treatmentMaternal-fetal outcomesShorter hospital stayOpioid overdose death ratesU.S. opioid epidemicOverdose death ratesRural-Urban Continuum CodesUtero buprenorphine exposureNAS symptomsPrescribe BuprenorphinePrescribing barriersHospital stayBuprenorphine exposureMedicaid insuranceAbstinence syndromeOpioid epidemicBuprenorphine accessEffective treatmentHigh incidence